Cancer Immunotherapy of TLR4 Agonist-Antigen Constructs Enhanced With Pathogen-Mimicking Magnetite Nanoparticles and Checkpoint Blockade of PD-L1

Small - Germany
doi 10.1002/smll.201803993
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Breast Care
SurgeryOncology
2016English

Systemic Immunotherapy of Superficial Mouse Bladder Cancer With Avelumab (MSB0010718C), an Anti-Pd-L1 Immune Checkpoint Inhibitor

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2015English

Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated With Checkpoint Blockade

Cancer immunology research
Cancer ResearchImmunology
2017English

Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer

Frontiers in Oncology
Cancer ResearchOncology
2020English

Pd-1 Immune Checkpoint Blockade Improves Anti-Cd20 Based Immunotherapy in Follicular Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Cancer Immunotherapy: PD-1 Blockade Cellular Vesicles for Cancer Immunotherapy (Adv. Mater. 22/2018)

Advanced Materials
Mechanics of MaterialsMaterials ScienceNanotechnologyMechanical EngineeringNanoscience
2018English

PD-1/PD-L1 Blockade: A New Promising Therapy for the Treatment of Pancreatic Cancer?

Pancreas - Open Journal
2018English

Oncolytic Virus and PD-1/PD-L1 Blockade Combination Therapy

Oncolytic Virotherapy
2018English

The Role of PD-1/PD-L1 Axis in Treg Development and Function: Implications for Cancer Immunotherapy

OncoTargets and Therapy
OncologyPharmacology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy